Treatment Recommendations in Non Valvular Atrial Fibrillation

Cardiology Update 2013 Treatment Recommendations in Non Valvular Atrial Fibrillation John Camm St. George’s University of London United Kingdom Advis...
Author: Gerard Horn
2 downloads 2 Views 6MB Size
Cardiology Update 2013

Treatment Recommendations in Non Valvular Atrial Fibrillation John Camm St. George’s University of London United Kingdom Advisor / Speaker : Astra Zeneca, Gilead, Merck, Menarini, Sanofi Aventis, Servier, Xention, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, Pfizer, Boston Scientific, Biotronik, Medtronic, St. Jude Medical, Actelion, GlaxoSmithKline, InfoBionics, Incarda, Johnson and Johnson, Mitsubishi, Novartis, Takeda

Guidelines for AF Management

ESC Guidelines: Camm J et al. Eur Heart J 2010;31:2369–429; ACCF/AHA/HRS Guidelines: Wann LS et al. J Am Coll Cardiol 2011;57:1330–7; CCS Guidelines: Skanes AC et al. Can J2Cardiol 2012;28:125– 136; You JY et al. ACCP Guidelines: Chest 2012;141;e531S–e575S; http://www.nice.org.uk/ta249

Anticoagulation - General Recommendations for prevention of thromboembolism in nonvalvular AF - general Recommendations

Class

Level

Antithrombotic therapy to prevent thromboembolism is recommended for all patients with AF, except in those patients (both male and female) who are at low risk (aged

Suggest Documents